| Market Cap | 1.33B 1.18B 1.09B 989M 1.85B 126B 1.89B 12.99B 5.23B 66.31B 4.98B 4.87B 209B | P/E 2026 * |
-4.81x | P/E 2027 * | -3.7x |
|---|---|---|---|---|---|
| Enterprise Value | 719M 642M 589M 536M 1B 68.05B 1.02B 7.03B 2.84B 35.92B 2.7B 2.64B 113B | EV / Sales 2026 * |
17.2x | EV / Sales 2027 * | 17.1x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 1.33B | |
| -2.37% | -4.19% | +39.49% | +63.21% | 63.77B | |
| -2.87% | +0.49% | +10.45% | +69.18% | 56.37B | |
| +0.62% | +2.11% | +20.22% | +102.56% | 54.62B | |
| -2.84% | -4.44% | +22.25% | +37.28% | 44.06B | |
| -1.81% | -1.93% | +16.63% | +99.80% | 42.11B | |
| -1.38% | +2.69% | +218.30% | +792.91% | 41B | |
| -5.47% | +24.76% | +98.34% | +87.34% | 34.92B | |
| +0.21% | -1.23% | +14.81% | +47.35% | 32.82B | |
| -1.72% | +17.86% | -40.93% | +339.82% | 24.7B | |
| Average | -1.80% | +7.73% | +44.39% | +182.16% | 43.82B | |
| Weighted average by Cap. | -1.89% | +5.64% | +45.02% | +164.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.82M 37.34M 34.26M 31.17M 58.44M 3.96B 59.6M 409M 165M 2.09B 157M 154M 6.6B | 53.42M 47.69M 43.76M 39.81M 74.64M 5.06B 76.12M 523M 211M 2.67B 200M 196M 8.43B |
| Net income | -246M -220M -202M -184M -344M -23.33B -351M -2.41B -972M -12.31B -925M -905M -38.89B | -363M -324M -297M -270M -507M -34.33B -517M -3.55B -1.43B -18.12B -1.36B -1.33B -57.23B |
| Net Debt | -608M -543M -498M -453M -850M -57.59B -867M -5.95B -2.4B -30.4B -2.28B -2.23B -96.01B | -415M -371M -340M -309M -580M -39.31B -592M -4.06B -1.64B -20.75B -1.56B -1.53B -65.54B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
